Oaktree Acquisition III Life Sciences EBIT

Oaktree Acquisition III Life Sciences (OACCW) currently reports a EBIT of $-1.2M as of June 2026. That compares with $1M in the prior-year period — down 215.7% year over year. That is above the sector sector average of $-25M. Use the charts on this page to explore Oaktree Acquisition III Life Sciences's EBIT history and peer comparisons.

Oaktree Acquisition III Life Sciences's EBIT decreased from $1M to $-1.2M — a 215.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Oaktree Acquisition III Life Sciences's EBIT of $-1.2M is higher than the its sector sector average of $-25M. That is roughly 95.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Oaktree Acquisition III Life Sciences reported $-1.2M in EBIT as of June 2026. That compares with $1M in the prior-year period — down 215.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-1.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-25M. From there, open related valuation or income-statement pages for Oaktree Acquisition III Life Sciences, and consider following OACCW for alerts when major investors trade the stock.